SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses the issuance of asset-backed securities (Notes) by Ford Credit Auto Owner Trust 2026-B, with the Registrant (Ford Credit Auto Receivables Two LLC) serving as the Depositor. The 8-K is filed to satisfy an undertaking to provide legality and tax opinions at the time of issuance, with counsel opinions attached as exhibits. This constitutes a material debt issuance creating a direct financial obligation.
View raw filing on EDGAR →Orla Mining Ltd. has entered into a court-approved plan of arrangement under the Canada Business Corporations Act whereby Equinox Gold Corp. will acquire all issued and outstanding shares of Orla Mining Ltd. in exchange for Equinox common shares (1.00 per Orla share) and US$0.0001 cash per share. The arrangement requires shareholder approval by at least 66⅔% vote at a special meeting scheduled for July 22, 2026.
View raw filing on EDGAR →Verastem disclosed preliminary clinical trial data from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375, a KRAS G12D inhibitor, demonstrating clinical efficacy and favorable safety profile across multiple cancer indications (pancreatic, colorectal, lung), and announced intent to collaborate with Erasca, Inc. on a preclinical combination study. This material clinical development milestone supports advancement toward Phase 2 trials and planned Phase 3 initiation by 1H 2027, materially affecting investor assessment of the company's pipeline and competitive position.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Fortress Biotech's June 17, 2026 annual meeting of stockholders, including voting outcomes for two proposals: (i) election of seven directors and (ii) ratification of KPMG LLP as independent auditor. The detailed vote tallies for each director and the auditor ratification constitute a classic shareholder_vote_results disclosure, which is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →Nyxoah received $15 million (€13.8 million) from the second tranche of its European Investment Bank (EIB) loan facility, representing a drawdown of an existing debt facility. This non-dilutive debt funding complements a concurrent equity raise, bringing total June 2026 capital raised to $110 million.
View raw filing on EDGAR →The filing discloses the adjournment of a special stockholder meeting to vote on TWO's proposed acquisition by CrossCountry Intermediate Holdco, LLC (an affiliate of CrossCountry Mortgage, LLC). The transaction involves a $12.00 per share cash offer representing a 21% premium to unaffected share price and is described as "fully financed" with 47 of 53 regulatory approvals secured and expected to close in August 2026. This is a material acquisition event requiring stockholder approval, making it an ma_activity disclosure.
View raw filing on EDGAR →This press release announces the design and regulatory alignment of a Phase 2b clinical trial (NOV-ERA study) for ontunisertib in fibrostenosing Crohn's disease, including FDA alignment on primary endpoints, protocol submission to regulatory agencies, and expected study initiation in H2 2026. This is a material operational/clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress in late-stage development of a key product candidate, but does not fit the discrete event categories (earnings, M&A, executive changes, etc.) and is best classified as an operational milestone.
View raw filing on EDGAR →Quoin announced FDA conditional approval of the brand name QYLEKI™ for QRX003, its investigational treatment for Netherton Syndrome, representing a material regulatory milestone in the drug development pathway. The company expects to initiate a Phase 3 pivotal study in H2 2026 and anticipates filing an NDA in 2027, advancing the lead candidate toward potential commercialization.
View raw filing on EDGAR →Eagle Point Trinity Senior Secured Lending Co issued 36,782.83 common shares for $373,000 in aggregate proceeds pursuant to subscription agreements, with the offer and sale exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →Kelly B. Rose, Senior Vice President, Legal, General Counsel and Corporate Secretary of ConocoPhillips, announced her retirement effective September 1, 2026. This is a clear departure of a named executive officer from a senior leadership position. The General Counsel role is material to investors' assessment of the company's legal and governance oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Orchestra BioMed's 2026 Annual Meeting of Stockholders held on June 23, 2026. The filing presents voting results for five proposals: election of three Class III directors (David P. Hochman, Darren R. Sherman, and Eric S. Fain), ratification of Ernst & Young LLP as independent auditor, approval of the 2026 Employee Stock Purchase Plan, advisory vote on named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed. This is a material governance event affecting investor understanding of board composition and corporate governance decisions.
View raw filing on EDGAR →The disclosure centers on the termination of Áine Miller, Senior Vice President and Head of Ireland Office, effective November 15, 2026, pursuant to a compromise agreement entered into on June 19, 2026 in connection with the Company's March 2026 restructuring. While the filing also mentions compensatory arrangements (RSU grant and pension contribution), the principal disclosed action is the executive's departure from the Company.
View raw filing on EDGAR →This exhibit is a formal Report of Voting Results filed pursuant to Section 11.3 of National Instrument 51-102, disclosing the outcomes of Eldorado Gold's Annual Shareholders Meeting held on June 23, 2026. It reports ballot results for election of nine directors, appointment of KPMG LLP as auditors, authorization of auditor remuneration, and an advisory vote on executive compensation — all standard shareholder-vote matters that materially affect governance and investor confidence in the company's leadership and oversight.
View raw filing on EDGAR →ASUR's Board proposes to internalize technical assistance and technology transfer services currently outsourced to ITA through a merger of one or more entities into ASUR, subject to shareholder approval. This represents a material acquisition or change in business structure. The transaction is expected to result in issuance of approximately 7.25 million new shares and is accompanied by extraordinary dividends of Ps. 10.00 per share, indicating a significant capital event. While the language frames this as "internalization" rather than a traditional M&A transaction, the substance—bringing an outsourced business function in-house through merger and equity issuance—constitutes material acquisition activity requiring shareholder approval.
View raw filing on EDGAR →This news release announces the results of Eldorado Gold's 2026 Annual Meeting of Shareholders held on June 23, 2026. It discloses the election of nine directors with specific voting tallies (votes for/against each nominee), shareholder approval of independent auditors, authorization of auditor compensation, and approval of an advisory resolution on executive compensation. The disclosure of director elections and shareholder votes at an annual meeting directly matches the `shareholder_vote_results` taxonomy category, and the results are material to investors assessing board composition and governance.
View raw filing on EDGAR →The Board appointed Daniel M. Skovronsky, M.D., Ph.D., to serve as a director effective June 16, 2026, increasing the Board size from nine to ten members. The disclosure centers on the appointment of a new director with relevant scientific and pharmaceutical R&D expertise, making this a clear exec_appointment event. The appointment is material as it represents a change in the composition of the Board of Directors.
View raw filing on EDGAR →The filing discloses the completion of all regulatory approvals for a material merger transaction. ProAssurance entered into a Merger Agreement on March 19, 2025, with The Doctors Company, whereby ProAssurance will become a wholly owned subsidiary. The disclosure confirms that as of June 23, 2026, all required regulatory approvals—including stockholder approval (June 24, 2025), FTC early termination (July 2, 2025), and all insurance regulator approvals—have been received, with closing expected on June 26, 2026. This represents a change of control and material acquisition activity requiring 8-K disclosure under Item 1.01 or 2.01.
View raw filing on EDGAR →Ioneer announced entry into non-binding letters of intent with KIND and Hyundai Engineering to advance the Rhyolite Ridge Lithium-Boron Project toward a Final Investment Decision. While the LOIs are explicitly non-binding and create no legal obligations, they represent a material strategic partnership milestone with major Korean entities that strengthens the path to project financing and construction. This is an operational/strategic business development event that would affect a reasonable investor's assessment of project execution risk and financing prospects.
View raw filing on EDGAR →Galectin announced positive feedback from an FDA Type C meeting regarding belapectin's development pathway for MASH cirrhosis, including FDA agreement on the primary endpoint (composite liver outcome including large esophageal varices), central endoscopy review methodology, and regulatory path toward full approval. This is a material regulatory milestone that clarifies the clinical development strategy and regulatory framework for the company's lead drug candidate, but does not fit the specific categories of earnings release, M&A activity, or other named event types. It is clearly operational/strategic in nature—a significant development program milestone with regulatory alignment.
View raw filing on EDGAR →Broadway Financial Corporation held its Annual Meeting of Stockholders on June 17, 2026, with voting results on four matters: election of three directors (Brian E. Argrett, Mary Ann Donovan, Mary M. Hentges) to serve until 2029; ratification of Crowe LLP as independent auditor for fiscal 2026; advisory approval of executive compensation; and stockholder selection of annual frequency for future advisory compensation votes.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from EverCommerce's June 18, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports the voting outcomes for two proposals: election of three Class II Directors (Amy Guggenheim Shenkan, John Rudella, and Mark Hastings) and ratification of Ernst & Young LLP as independent auditor. All three director nominees and the auditor ratification passed with overwhelming majorities, representing a routine but material governance event that affects investor understanding of board composition and audit oversight.
View raw filing on EDGAR →DevvStream received a Nasdaq Hearings Panel determination to suspend its securities from Nasdaq effective June 24, 2026, due to noncompliance with the Minimum Bid Price Rule (Rule 5550(a)(2)) and failure to satisfy the Net Income Rule (Rule 5550(b)). The filing explicitly discloses the suspension decision and the Company's intent to appeal to the Listing Council, with shares expected to transfer to the Pink Limited Market and potentially OTCQB. This is a clear delisting risk event under Item 3.01.
View raw filing on EDGAR →This Item 5.07 disclosure presents the complete voting results from Genco's June 18, 2026 Annual Meeting of Shareholders, including election of six directors, advisory vote on executive compensation, approval of equity plan amendment, ratification of auditors, ratification of shareholder rights agreement, and rejection of two shareholder proposals. The detailed tabulation of votes for and against each proposal is the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →IFF entered into a $1 billion senior unsecured delayed draw term loan facility on June 23, 2026, to refinance €800 million of Senior Notes due September 25, 2026. This represents a material creation of a new direct financial obligation.
View raw filing on EDGAR →Sensient entered into a Credit Agreement on June 18, 2026, establishing an unsecured delayed-draw term loan facility of up to $400 million with a five-year maturity, to be used for refinancing existing indebtedness and general corporate purposes.
View raw filing on EDGAR →The Board approved and filed a one-for-thirty-five reverse stock split, effective June 25, 2026, pursuant to stockholder authorization granted at the August 4, 2025 special meeting. The reverse split constitutes an amendment to the Certificate of Incorporation affecting the company's capital structure and security holder rights.
View raw filing on EDGAR →Green Dot shareholders voted on June 23, 2026 to approve four proposals: adoption of the Merger Agreement with CommerceOne and Smith Ventures (99.6% in favor), approval of the Separation Agreement (99.6% in favor), advisory approval of transaction-related executive compensation (87.7% in favor), and adjournment authority (98.8% in favor). All proposals were approved by the requisite vote, representing a critical milestone in a transformative transaction involving the acquisition of Green Dot Bank by CommerceOne and the separation of Green Dot's fintech operations to Smith Ventures.
View raw filing on EDGAR →The exhibit is a press release announcing results of Skeena's Annual General Meeting held June 22, 2026, disclosing shareholder approval of director reelection, the Rolling Omnibus Incentive Plan, auditor reappointment, and board size. The detailed voting table shows voting percentages for each director nominee. While the exhibit also includes management changes (appointment of Ryan Maloney as VP Corporate Development and transition of Justin Himmelright to Strategic Advisor), the primary disclosed event is the AGM vote results, which is material to investors as it confirms board composition and governance approvals. The management changes are secondary announcements within the same release.
View raw filing on EDGAR →This press release announces positive metallurgical test results for the Ninaaskumuwin lithium discovery on Fury's Elmer East project, demonstrating feasibility of producing a Direct Shipping Ore concentrate grading 6.024% Li₂O with 76.66% recovery through Dense Media Separation. The disclosure is a material operational/exploration milestone that would affect a reasonable investor's assessment of the company's lithium asset value and development potential, but does not fit the specific event categories (it is neither an earnings release, M&A activity, nor a discrete financial obligation).
View raw filing on EDGAR →Anika Therapeutics held its Annual Meeting on June 18, 2026, with stockholders voting on five proposals: election of three Class III directors (Fischetti, Henneman, Griffin), ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, approval of the Revised Seventh Amended Plan increasing equity reserves, and amendment of the ESPP increasing share reserves. The filing reports the final voting results for each proposal.
View raw filing on EDGAR →Westport completed a registered direct offering of 1.6 million common shares and 3.25 million pre-funded warrants, combined with a concurrent private placement of 4.85 million warrants, raising approximately US$10 million in gross proceeds with potential for an additional US$10 million upon warrant exercise. The offering involved both registered and unregistered securities (private placement warrants under Section 4(a)(2) and Regulation D), materially diluting existing shareholders.
View raw filing on EDGAR →The filing discloses a conditional $17.5 billion DOE financing commitment to support Westinghouse nuclear reactor deployment, in which Brookfield holds a 51% ownership stake. This is a material operational and strategic development affecting Brookfield's nuclear energy business, but it is conditional and does not constitute a completed transaction or M&A activity. The event is best classified as an operational milestone rather than a specific financial or governance category.
View raw filing on EDGAR →This exhibit is a Notice of Special Meeting of Shareholders and accompanying Proxy Statement soliciting shareholder approval for one or more reverse stock splits at a cumulative exchange ratio between one-for-two and one-for-250. While reverse stock splits are governance matters requiring shareholder approval, this is a pre-vote notice and proxy solicitation document, not a shareholder vote result. The disclosure is material because reverse stock splits affect share structure and trading price, and the company explicitly notes NASDAQ listing compliance concerns (minimum $1.00 bid price requirement). This is a governance event that does not fit the specific `shareholder_vote_results` category (which applies post-vote) but is clearly governance-related and material to investors.
View raw filing on EDGAR →The press release announces a 1-for-25 reverse stock split effective June 26, 2026, reducing outstanding shares from ~15.1 million to ~605,000. While a reverse split itself is not a new issuance, it is a capital structure event that signals potential delisting risk mitigation—the Company explicitly states the purpose is "to maintain compliance with Nasdaq's continued listing requirements," suggesting the stock price had fallen below minimum thresholds. This is material to investors as it reflects compliance pressure and dilution concerns, though the classification is somewhat ambiguous between `dilutive_issuance` (capital structure change affecting share value) and `delisting_risk` (the underlying compliance issue). The reverse split is the disclosed action, making `dilutive_issuance` the best fit, though confidence is moderate given the reverse split itself does not create new shares.
View raw filing on EDGAR →This press release announces the filing and mailing of meeting materials for a special shareholder meeting to approve a business combination (plan of arrangement) between Equinox Gold and Orla Mining. The transaction involves Equinox Gold acquiring all outstanding common shares of Orla Mining, with each Orla share exchanged for 1.00 Equinox Gold common share and US$0.0001 in cash, resulting in a combined company where existing Equinox Gold and former Orla shareholders will own approximately 67% and 33%, respectively. This is a material acquisition and change of control event requiring shareholder approval.
View raw filing on EDGAR →This Material Change Report discloses operational disruptions at Alamos Gold's Young-Davidson mine caused by seismic events (June 12, 2026) and power outages (May 2026), resulting in revised production guidance downward by 12% for Q2 2026 and expectations that full-year 2026 consolidated production will fall below the low end of prior guidance with costs above guidance. While the disclosure includes operational updates on Island Gold District and hedging activities, the material event is the operational disruption and associated guidance revision, which is an operational matter affecting production and costs rather than a discrete event type like impairment or restructuring.
View raw filing on EDGAR →Allot's Board of Directors has authorized a $40 million share repurchase program, which is a return of capital to shareholders. The announcement explicitly states the program "reflects the Board's confidence in Allot's long-term growth strategy, strong financial position" and CEO Harari characterizes it as "an attractive use of our excess capital, that allows us to create increased value for our shareholders." Share repurchases are a form of capital distribution and would materially affect a reasonable investor's assessment of capital allocation and shareholder value creation.
View raw filing on EDGAR →The 6-K announces the appointment of two directors, Mr. Erez Wiener and Mr. Daniel Schutz, effective July 1, 2026. This is a clear executive/governance appointment. The disclosure includes detailed biographical information for both appointees, including Wiener's prior service as CEO of the Company and Schutz's family relationship to the CEO and controlling shareholder Joseph Williger, making this material to investors' assessment of board composition and potential conflicts of interest.
View raw filing on EDGAR →The Company entered into a Securities Purchase Agreement on June 23, 2026, to issue a convertible promissory note ($1.5M principal at initial closing, up to $2M total) and warrants to purchase 468,978 Class A ordinary shares. The convertible note and warrant structure creates significant dilution to existing shareholders through conversion and exercise rights. This is a classic PIPE-like transaction raising capital through unregistered securities with conversion/exercise features, fitting the dilutive_issuance taxonomy.
View raw filing on EDGAR →The exhibit announces a 30-for-1 reverse stock split effective June 23, 2026, explicitly stated as "primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its Nasdaq listing." This disclosure directly addresses delisting risk and the company's remedial action to avoid loss of listing status, which is material to investors assessing the registrant's continued market access and trading liquidity.
View raw filing on EDGAR →PRA Group held its 2026 Annual Meeting of Stockholders on June 16, 2026, with voting results on four matters: election of nine directors, ratification of Ernst & Young LLP as independent auditor, advisory vote on named executive officer compensation, and amendment to the 2022 Omnibus Incentive Plan increasing share authorization by 3,500,000 shares.
View raw filing on EDGAR →Exhibit 99.1 and 99.2 announce a cash dividend adjustment and record date. The company adjusted the per-share dividend from NT$2.60 to NT$2.60808262 due to share repurchases and restricted stock cancellations, with a payment date of 2026/07/30. This is a material dividend distribution event affecting shareholders.
View raw filing on EDGAR →ChipMOS disclosed the acquisition of plant engineering works and equipment accessories from MAU TSWEN MECHANICAL ENGINEERING CO., LTD. for NT$512,231 thousand (approximately $16.5 million USD), completed between July 2, 2025 and June 23, 2026. The transaction was approved by the Company President on June 23, 2026, and is disclosed pursuant to Taiwan Stock Exchange material information disclosure rules. While this is a capital asset acquisition for manufacturing purposes rather than a business combination or M&A activity, the substantial amount and operational significance of acquiring plant and equipment warrant classification as a material operational event that would affect a reasonable investor's assessment of the company's capital deployment and operational capacity.
View raw filing on EDGAR →This is a press release announcing Jiayin Group's unaudited financial results for Q1 2026, dated June 23, 2026. The exhibit discloses quarterly financial performance including net revenue of RMB 756.7 million (down 57.4% YoY), a net loss of RMB 61.7 million (versus net income of RMB 539.5 million in Q1 2025), transaction volume of RMB 19.3 billion (down 45.8% YoY), and detailed consolidated balance sheets and statements of comprehensive income. The dramatic revenue decline, shift from profitability to loss, and significant operational deterioration are material to investors' assessment of the company's financial condition and performance.
View raw filing on EDGAR →Paramount Gold announced completion of a Technical Report Summary Initial Assessment (S-K 1300 compliant) for the Sleeper Gold Project, a past-producing mine, disclosing positive project economics with after-tax NPV of $402M–$867M and IRR of 45–66%, along with an updated mineral resource estimate showing a 5% increase in Measured & Indicated Resources and 90% increase in Inferred Resources. The company plans to advance toward production restart with an $8.7M advancement program and permitting activities.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from an annual and special meeting held on June 22, 2026. The filing reports the outcomes of three proposals: fixing the board size at seven directors, electing seven director nominees, and appointing PricewaterhouseCoopers LLP as independent auditor. All proposals were approved with detailed vote tallies provided for each matter, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →PLDT discloses that VITRO Inc. (a wholly-owned subsidiary of ePLDT, itself a wholly-owned subsidiary of PLDT) has submitted an application for listing on the Philippine Stock Exchange Main Board in connection with a proposed initial public offering. This is a material operational and strategic event—a subsidiary's IPO would affect PLDT's capital structure, ownership stake, and financial position—but does not fit the specific categories of M&A activity (which typically involves acquisition or disposition of assets/control), dilutive issuance (which applies to the parent issuer's own equity), or other named types. The disclosure is clearly operational/strategic in nature, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →Phathom announced completion of enrollment in its Phase 2 pHalcon-EoE-201 clinical trial for VOQUEZNA in eosinophilic esophagitis, with 95 patients enrolled at 41 U.S. sites and topline results anticipated in Q4 2026. This is a material operational/clinical milestone for a biopharmaceutical company's drug development program, but does not fit the specific categories of earnings release, M&A, impairment, litigation, or other named event types. The disclosure is material to investors assessing the company's pipeline progress and regulatory prospects.
View raw filing on EDGAR →LM Funding announced a strategic expansion into high-performance computing and AI infrastructure, including orders for GPU hardware and marketing of 10 megawatts of available power capacity to AI customers, with potential $20M–$50M annual revenue opportunity. This represents a material pivot from the company's primary Bitcoin mining business, leveraging its existing 26-megawatt power infrastructure to enter a new business line.
View raw filing on EDGAR →Boundless Bio entered into a definitive merger agreement with Serapha Bio, whereby Serapha will be the surviving entity and Boundless stockholders will own approximately 3.7% of the combined company post-closing. The transaction includes a concurrent $230 million private placement financing and is expected to close in Q4 2026.
View raw filing on EDGAR →